Abstract 5729
Background
Inactivation of tumor suppressor p53 is a common event in tumor progression. In almost 50% of cases p53 inactivation is caused by mutations that primarily affect DNA-binding domain. Oncogenic missense mutation Y220C is the ninth most common for p53 and is annually observed in ∼100,000 new diagnosed cancer cases worldwide. Presence of this mutation disturbs tertiary structure of the p53 DNA-binding domain that further leads to destabilization of the whole protein, its partial denaturation and loss of transcriptional activity. In some cases, p53 mutations result in more aggressive cancer cells and alter drug sensitivity.
Methods
We employ CRISPR-Cas9 gene editing technology to generate p53 knock-out and Y220C mutant MCF-7 cell lines. Quantitative analysis of alterations in intracellular protein levels were performed by immunoblotting, analysis of p53-dependent gene expression by quantitative real-time reverse transcription PCR; cell proliferation and chemotherapy cytotoxicity by MTS test. Statistical analysis was performed using ANOVA and Holm-Sidak method for multiple comparison, p ≤ 0.05 was considered to be statistically significant.
Results
We have confirmed that p53 mutation Y220C leads to p53 inactivation. Proliferation rate of p53 knockout and mutant MCF-7 cell lines was 15% higher than wild type. We have shown statistically significant decrease in topotecan cytotoxicity towards knockout and mutant cells compared to wild-type – 14% and 26%, respectively.
Conclusions
Decline of topotecan cytotoxicity in mutant and knockout cells can be explained by topotecan-mediated induction of p53 that leads to higher levels of cell death in wild-type MCF-7. References Bulatov, E., Zagidullin, A., Valiullina, A., Sayarova, R., Rizvanov, A. (2018). Small molecule modulators of RING-type E3 ligases: MDM and Cullin families as targets. Frontiers in pharmacology, 9, 450.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Albert Rizvanov.
Funding
Grant of the President of the Russian Federation (MK-4253.2018.4).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4294 - The Patient Voice: An Irish Survey of Nutrition Attitudes & Access to Dietetic Care Throughout the Cancer Journey
Presenter: Erin Stella Sullivan
Session: Poster Display session 1
Resources:
Abstract
1925 - Homcology: home chemotherapy delivery in a simultaneous care project for frail advanced cancer patients
Presenter: Claudio Chini
Session: Poster Display session 1
Resources:
Abstract
4701 - Treatment-related adverse events and tolerability in patients with advanced non-squamous non-small cell lung cancer treated with first-line checkpoint inhibitors in combination with chemotherapy
Presenter: Ruth D'cunha
Session: Poster Display session 1
Resources:
Abstract
2985 - Clinical utility of a systematic toxicity assessment form (STAF) in patients with breast cancer receiving adjuvant or neoadjuvant therapy.
Presenter: Jwa Hoon Kim
Session: Poster Display session 1
Resources:
Abstract
2358 - Physicians’ satisfaction with Health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients.
Presenter: Guillaume Mouillet
Session: Poster Display session 1
Resources:
Abstract
5172 - Predictors of Survival in Patients with Incurable Cancer
Presenter: Erin Stella Sullivan
Session: Poster Display session 1
Resources:
Abstract
2281 - Patients and Physicians' Satisfaction with Telemedicine (TM) in Cancer Care and Factors that Correlate with a Positive Patient’s Experience
Presenter: Hurria Gondal
Session: Poster Display session 1
Resources:
Abstract
2193 - Adherence to ESMO 2014 guidelines on bone-targeting agent (BTA) initiation for breast and prostate cancer patients: real-world insights from practicing European physicians
Presenter: Alex Rider
Session: Poster Display session 1
Resources:
Abstract
2200 - Use of skeletal-related events preventive agents in patients with solid tumours and bone metastases in central Denmark
Presenter: Anders Boysen
Session: Poster Display session 1
Resources:
Abstract
2504 - Inadequacy of current definition and staging system of Medication-Related Osteonecrosis of Jaw (MRONJ) released by AAOMS : a Computed Tomography study in 151 cancer and myeloma patients
Presenter: Vittorio Fusco
Session: Poster Display session 1
Resources:
Abstract